Elite in Oligodendroglioma

Dr. David A. Reardon

Hematology Oncology | Hematology | Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Center For Neuro-Oncology
450 Brookline Avenue, 
Boston, MA 
Offers Telehealth
Elite in Oligodendroglioma
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Center For Neuro-Oncology
450 Brookline Avenue, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Reardon is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Reardon is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy.

His clinical research consists of co-authoring 352 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Oligodendroglioma.

Graduate Institution
Tufts University School Of Medicine, 1986
Residency
Johns Hopkins, 1989
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Pediatric Hematology-Oncology
Pediatrics
Fellowships
University of Michigan Health System, 1992
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Center for Neuro-Oncology
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-2166

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
Enrollment Status: Completed
Publish Date: November 03, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients
Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients
Enrollment Status: Completed
Publish Date: October 22, 2025
Intervention Type: Drug
Study Drugs: ASP8374, Cemiplimab
Study Phase: Phase 1
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Study Phase: Phase 2
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Bevacizumab
Study Phase: Phase 2
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progressive/Recurrent Meningioma
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progressive/Recurrent Meningioma
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drugs: AMG 596, AMG 404
Study Phase: Phase 1
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Bevacizumab
Study Phase: Phase 2
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drugs: BLZ945, PDR001
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Enrollment Status: Completed
Publish Date: April 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

352 Total Publications

Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.
Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.
Journal: JAMA network open
Published: November 25, 2025
View All 352 Publications
Similar Doctors
Distinguished in Oligodendroglioma
Dr. Lakshmi S. Nayak
Oncology | Neurology
Distinguished in Oligodendroglioma
Dr. Lakshmi S. Nayak
Oncology | Neurology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lakshmi Nayak is an Oncologist and a Neurologist in Boston, Massachusetts. Dr. Nayak is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Astrocytoma, Glioma, Glioblastoma, and Brain Tumor. Dr. Nayak is currently accepting new patients.

Distinguished in Oligodendroglioma
Dr. Gautami S. Rao
Hematology Oncology | Hematology | Oncology
Distinguished in Oligodendroglioma
Dr. Gautami S. Rao
Hematology Oncology | Hematology | Oncology

Foundation Medical Partners Inc

10 Prospect St, 
Nashua, NH 
 (34.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gautami Rao is a Hematologist Oncology specialist and a Hematologist in Nashua, New Hampshire. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Paget Disease of the Breast, Intraductal Papilloma, Inflammatory Breast Cancer, and Hodgkin Lymphoma. Dr. Rao is currently accepting new patients.

Distinguished in Oligodendroglioma
Dr. Nancy Wang
Hematology Oncology | Pediatric Neurology | Neurology
Distinguished in Oligodendroglioma
Dr. Nancy Wang
Hematology Oncology | Pediatric Neurology | Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nancy Wang is a Hematologist Oncology specialist and a Pediatric Neurologist in Boston, Massachusetts. Dr. Wang is rated as a Distinguished provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Astrocytoma, Glioblastoma, Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, and Awake Craniotomy. Dr. Wang is currently accepting new patients.

VIEW MORE OLIGODENDROGLIOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reardon's expertise for a condition
ConditionClose
  • Elite
  • Astrocytoma
    Dr. Reardon is
    Elite
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Brain Tumor
    Dr. Reardon is
    Elite
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Glioblastoma
    Dr. Reardon is
    Elite
    . Learn about Glioblastoma.
    See more Glioblastoma experts
  • Glioma
    Dr. Reardon is
    Elite
    . Learn about Glioma.
    See more Glioma experts
  • Gliomatosis Cerebri
    Dr. Reardon is
    Elite
    . Learn about Gliomatosis Cerebri.
    See more Gliomatosis Cerebri experts
  • Metastatic Brain Tumor
    Dr. Reardon is
    Elite
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
View All 7 Elite Conditions
  • Distinguished
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Reardon is
    Distinguished
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Reardon is
    Distinguished
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Ependymoma
    Dr. Reardon is
    Distinguished
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Gliosarcoma
    Dr. Reardon is
    Distinguished
    . Learn about Gliosarcoma.
    See more Gliosarcoma experts
  • Neuroepithelioma
    Dr. Reardon is
    Distinguished
    . Learn about Neuroepithelioma.
    See more Neuroepithelioma experts
  • Pediatric Low-Grade Glioma (pLGG)
    Dr. Reardon is
    Distinguished
    . Learn about Pediatric Low-Grade Glioma (pLGG).
    See more Pediatric Low-Grade Glioma (pLGG) experts
View All 8 Distinguished Conditions
  • Advanced
  • Brain Stem Cancer
    Dr. Reardon is
    Advanced
    . Learn about Brain Stem Cancer.
    See more Brain Stem Cancer experts
  • Choroid Plexus Papilloma
    Dr. Reardon is
    Advanced
    . Learn about Choroid Plexus Papilloma.
    See more Choroid Plexus Papilloma experts
  • Diffuse Midline Glioma H3 K27M-Mutant
    Dr. Reardon is
    Advanced
    . Learn about Diffuse Midline Glioma H3 K27M-Mutant.
    See more Diffuse Midline Glioma H3 K27M-Mutant experts
  • Medulloblastoma
    Dr. Reardon is
    Advanced
    . Learn about Medulloblastoma.
    See more Medulloblastoma experts
  • Non-Hodgkin Lymphoma
    Dr. Reardon is
    Advanced
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Pituitary Tumor
    Dr. Reardon is
    Advanced
    . Learn about Pituitary Tumor.
    See more Pituitary Tumor experts
View All 7 Advanced Conditions
  • Experienced
  • Congenital Generalized Fibromatosis
    Dr. Reardon is
    Experienced
    . Learn about Congenital Generalized Fibromatosis.
    See more Congenital Generalized Fibromatosis experts
  • Desmoid Tumor
    Dr. Reardon is
    Experienced
    . Learn about Desmoid Tumor.
    See more Desmoid Tumor experts
  • Dysembryoplastic Neuroepithelial Tumors (DNET)
    Dr. Reardon is
    Experienced
    . Learn about Dysembryoplastic Neuroepithelial Tumors (DNET).
    See more Dysembryoplastic Neuroepithelial Tumors (DNET) experts
  • Gastric Lymphoma
    Dr. Reardon is
    Experienced
    . Learn about Gastric Lymphoma.
    See more Gastric Lymphoma experts
  • Hemangiopericytoma
    Dr. Reardon is
    Experienced
    . Learn about Hemangiopericytoma.
    See more Hemangiopericytoma experts
  • Hypothalamic Tumor
    Dr. Reardon is
    Experienced
    . Learn about Hypothalamic Tumor.
    See more Hypothalamic Tumor experts
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.